Sat.Dec 10, 2022 - Fri.Dec 16, 2022

article thumbnail

Opinion: Hospice care needs saving

STAT

Hospice in America is gravely ill. An extensive investigation jointly published by The New Yorker and ProPublica documented outright fraud, predatory practices, and flagrant mistreatment by specific publicly traded and private equity-owned hospice companies.

article thumbnail

Can pharma quit Twitter? Social strategy evolves as Musk changes the platform

PharmaVoice

A breakdown of how Twitter’s recent shifts are impacting pharma, and how the industry should navigate the platform in 2023.

267
267
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Four ways Biogen is tackling digital innovation in neurological disease

pharmaphorum

Digital transformation in pharma is not a singular endeavour. It can mean everything from patient-facing disease management apps and wearables to background AI dramatically altering drug discovery or radiological imaging. So, when a life sciences company embarks on a project of digital transformation or innovation, it’s really embarking on multiple projects that span the wide world of pharmaceutical operations.

Hospitals 137
article thumbnail

Female Board Members Are Good for Business

PharmExec

Perspectives from a board member and an aspiring board member on how to increase the number of qualified women on boards.

136
136
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

STAT+: Nine in 10 health care companies with financial stress are owned by private equity

STAT

Almost 90% of the health care companies deemed to be under financial stress by a leading credit rating agency are owned by private equity , a stark indicator of the toll financial investors have taken on a vital sector. The striking finding is part of a new Moody’s Investors Service report released this week that shows broad turbulence throughout an industry weakened by private equity’s practice of loading companies with debt, making them less resilient to challenges like Covid-19,

Hospitals 363
article thumbnail

The pharma giants making the biggest strides with global drug access

PharmaVoice

A recent report ranks the top 20 pharma companies by how well they’re boosting a critical component of health equity.

264
264

More Trending

article thumbnail

CSL closes on EU approval for haemophilia B gene therapy

pharmaphorum

CSL’s gene therapy for haemophilia B has been recommended for approval by the EMA’s human medicine committee, setting up a decision by the European Commission early next year. The positive opinion for etranacogene dezaparvovec – which was approved as Hemgenix by the FDA last month – raises the prospect of the first one-time therapy in the EU for the bleeding disorder, which affects around 1 in 50,000 of the population, according to the European Haemophilia Network (EUHANET).

126
126
article thumbnail

STAT+: Bone marrow transplant patients could be spared from ‘bland’ diet, study finds

STAT

Whenever a hematopoietic cell transplant patient tries to get a family member to sneak food in past the nurses, Federico Stella, a resident hematologist at the University of Milan, remembers. One was a girl who tried to get her sister to bring her a panettone, a Milanese sweet bread usually eaten around the holidays. A week before Christmas, the sister tried to hide the panettone in a bag.

363
363
article thumbnail

The 2023 PharmaVoice Year in Preview

PharmaVoice

Here’s a look at how industry leaders are navigating the key issues of 2023.

264
264
article thumbnail

First patient given base-edited CAR T cells

European Pharmaceutical Review

A thirteen-year-old patient with relapsed T-cell acute lymphoblastic leukaemia (T-ALL) has been the first to be treated with base-edited T-cells via CD7 Chimeric Antigen Receptor (CAR)-T cell therapy, which enabled them to achieve remission 28 days later. . A unique clinical trial for T-ALL. The patient enrolled in the ongoing clinical trial ( NCT05397184 ) went on to receive a second bone marrow transplant after the therapy.

article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

Novartis joins Cancer Research UK on rare cancers study

Pharma Times

DETERMINE trial aims to discover if current treatments could benefit patients with other cancer types

124
124
article thumbnail

STAT+: Moderna says cancer vaccine reduces melanoma’s return by 44%

STAT

An experimental cancer vaccine being developed by the biotechnology firm Moderna and the drug giant Merck reduced the risk that melanoma would return after surgery or that patients would die by 44%, the company said. The data, made public in a press release, represent the first evidence of an effective individualized cancer vaccine based on mRNA, the technology used in the Covid shots.

Vaccines 361
article thumbnail

At the heart of hematology breakthroughs, a community of researchers and patients comes together

PharmaVoice

As new and advanced therapies are revealed at the annual meeting of the American Society of Hematology this week, the patients are always at the center.

246
246
article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

People who live with narcolepsy — about one out of every 2,000 Americans — don’t have many options when it comes to treatment. The milder form of narcolepsy includes symptoms of excessive daytime sleepiness and can be treated with a stimulant like Provigil, Adderall, or Dexedrine in order to get people through their day. In addition to excessive daytime sleepiness, up to 60% of narcolepsy cases include cataplexy, which is a sudden loss of muscle control.

article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

Kidney Research UK concerned by NICE process

Pharma Times

Organisation believes the guidance would leave renal patients with no effective treatment outside hospital

Hospitals 123
article thumbnail

Covid vaccines averted 3 million deaths in U.S., according to new study

STAT

This Wednesday will mark two years since nurse Sandra Lindsay became the first person in the U.S. to receive a Covid-19 vaccine outside of a clinical trial. A study released Tuesday by the Commonwealth Fund shows that in those two years, the Covid vaccines have averted over 3 million deaths in the U.S. The Centers for Disease Control and Prevention estimates that more than 1 million Americans have died from Covid-19 since the onset of the pandemic.

Vaccines 360
article thumbnail

Spotlight on oncology drug development & its future

PharmaVoice

Learn why an informed, holistic view is needed to succeed in today’s complex and dynamic landscape.

article thumbnail

mRNA vaccine plus KEYTRUDA® improve melanoma survival

European Pharmaceutical Review

Moderna, Inc. and Merck have announced that a Phase IIb trial ( NCT03897881 ) of a personalised mRNA cancer vaccine (mRNA-4157/V940), in combination with KEYTRUDA ® , Merck’s anti-PD-1 therapy, demonstrated the first randomised evidence that a personalised neoantigen approach may be beneficial in treating melanoma. Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA ® reduced the risk of recurrence or death by 44 percent (HR=0.56 [95 percent CI, 0.31-1.08]; one-sided p-valu

Vaccines 116
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Pfizer and Anumana boost detection of cardiovascular disease

Pharma Times

Partnership will support development of new algorithm and identify at risk patients

122
122
article thumbnail

STAT+: Emerging class of genetically targeted drugs induce remissions in leukemia patients

STAT

NEW ORLEANS — An emerging class of genetically targeted drugs is inducing remissions in about one-third of patients with advanced leukemia, according to updates Saturday from separate clinical trials. Two biotechs — Syndax Pharmaceuticals and Kura Oncology — are developing their own versions of so-called menin inhibitors that have the potential to become effective treatments for certain types of genetically defined acute myeloid leukemia (AML), a rapidly progressing bone mar

350
350
article thumbnail

How one of the world’s most prolific inventors is guiding a plan to tackle all disease

PharmaVoice

Steve Quake, science head at the Chan Zuckerberg Initiative, is leveraging personal experiences and a deep background in R&D to lead an ambitious 100-year plan.

147
147
article thumbnail

340B program continues to drive shift in care to more expensive hospital settings

PhRMA

Yet another study highlights the unintended consequences of the 340B program, which is increasing costs for patients and the health care system as a whole. In this case, the Berkeley Research Group (BRG) found that nearly 36% of all Medicare Part B therapy sales occurred at 340B hospitals in 2021 , up nearly 17 percentage points since 2012, meaning care is moving from physician offices and non-340B hospitals to 340B hospitals.

Hospitals 114
article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

PrecisionLife and Ono Pharmaceutical enter into new R&D link up

Pharma Times

R&D partnership will identify and develop novel therapeutic targets for future therapies

116
116
article thumbnail

STAT+: ‘We’ve got a new target’: Bispecific antibody for multiple myeloma succeeds in mid-stage trial

STAT

NEW ORLEANS — Researchers had hoped in recent years that a protein called GPRC5D might offer a new way to get the immune system to hunt down and destroy multiple myeloma cells. Now, the results of a Phase 2 study on a bispecific antibody targeting this protein offers confirmation. The data, presented Saturday at the annual American Society of Hematology conferences, wowed a crowd of attendees, including clinicians who began excitedly imagining how to use the new drug in practice.

Immunity 314
article thumbnail

Woman of the Week: Exelixis’ Dr. Vicki Goodman

PharmaVoice

With several blockbuster products under her belt, veteran oncologist and drug developer Dr. Vicki Goodman is looking to further evolve Exelixis’ pipeline to address hard-to-treat cancers.

article thumbnail

Inizio acquires Evolution Road

PharmExec

The move bolsters Evoke’s digital innovation and omnichannel offering.

111
111
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

PhoreMost and ThinkCyte partner to develop AI-based drug discovery

Pharma Times

The partnership combines systems in order to identify subtle phenotypic changes in living cells

113
113
article thumbnail

No one’s quite sure how to fix pulse oximeters. The FDA asked this lab to find answers

STAT

SAN FRANCISCO — The discovery that fingertip oxygen-measuring devices might contribute to health disparities because they appear to work less well on patients with darker skin has roiled the world of pulse oximetry, a $2 billion industry that now faces stricter regulations and pressure to address bias in the development and testing of its devices.

297
297
article thumbnail

A New Dimension in New Drug Molecules Research with Nanome’s VR technology [Interview]

Pharma Mirror

The COVID-19 pandemic challenged researchers to discover life-saving treatments at an unprecedented pace. While these researchers rose to the occasion by discovering drugs faster than ever before, variants continue to challenge the world in addressing COVID-19. New innovations in computer-aided drug discovery tools could dramatically accelerate the study of new variants.

105
105
article thumbnail

Alternatives to Semaglutide for Weight Loss

Compounding Pharmacy of America

Semaglutide is highly effective as a weight loss drug, but it is not ideal for every situation. Powerful fat-burning alternatives can achieve similar results. The post Alternatives to Semaglutide for Weight Loss appeared first on The Compounding Pharmacy of America.

article thumbnail

Scottish Medicines Consortium agrees to use of Rinvoq

Pharma Times

Therapy will now treat adults across Scotland with moderate rheumatoid arthritis

112
112